

3D CELL CULTURES: TECHNOLOGIES AND GLOBAL MARKETS



BIO140A
January 2015

Robert Hunter
Project Analyst

ISBN: 1-62296-006-8



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	2
INTENDED AUDIENCE	2
METHODOLOGY AND INFORMATION SOURCES	3
ANALYST'S CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	3
BCC RESEARCH WEBSITE	3
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
<i>SUMMARY TABLE THREE-DIMENSIONAL CELL CULTURE MARKET, THROUGH 2019 (\$ MILLIONS/%)</i>	8
<i>SUMMARY FIGURE THREE-DIMENSIONAL CELL CULTURE MARKET, 2013-2019 (\$ MILLIONS)</i>	9
CHAPTER 3 TISSUE AND CELL CULTURE	11
OVERVIEW	11
TISSUE	11
<i>TABLE 1 TISSUE TYPES</i>	11
CELLS	12
CELL TYPES	12
<i>TABLE 2 CELL TYPES</i>	13
TISSUE CULTURE AND CELL CULTURE DEFINITIONS	14
OBTAINING CELL CULTURES	14
ISOLATING CELLS FROM TISSUES	14
MAINTAINING CELLS IN CULTURE	14
PLATING DENSITY AND SUB-CULTURING	15
CRYOGENIC STORAGE	15
OBTAINING CELLS FROM OTHER SOURCES: ISSUE OF CROSS-CONTAMINATION	15
CELL TYPES BASED ON MORPHOLOGY	16
CELL TYPES BASED ON HYBRIDOMAS	16
CELL CULTURE: BASIC REQUIREMENTS	16
AVOIDING CONTAMINATION	16
IMPORTANT INDICATORS OF CELL CULTURE HEALTH	17
MAINTAINING OPTIMAL CELL CULTURE CONDITIONS	17
BASIC CELL CULTURE SYSTEMS	17
ADHERENT CELLS REQUIRING ATTACHMENT SUBSTRATE	17
SUSPENSION CELL CULTURES	18
HISTORY AND EARLY APPLICATIONS	18
INVENTION OF TISSUE CULTURE	18
DEVELOPMENT OF SUSTAINED CELL LINES	19
FIRST CELL CULTURE FLASK AND RIGOROUS TECHNIQUES	19
LINDBERGH: THE CELL CULTURE EQUIPMENT PIONEER	20

TOPIC	PAGE NO.
Perfusion Chamber	20
Cell Culture Flask	20
Centrifugal Filter for Serum Isolation	20
ESTABLISHING CONTINUOUS CELL LINES	20
KEY EQUIPMENT DEVELOPMENTS	21
VACCINE DEVELOPMENT AS CATALYST	21
Background and Drawbacks of Live Animal Approaches	21
Efforts to Develop Polio Vaccine in Cell Culture	22
CELL STRAINS AND CELL LINES	23
VACCINES DEVELOPED USING HUMAN CELL STRAINS	23
CONTINUED CATALYST	24
CHAPTER 4 TISSUE AND CELL CULTURE SYSTEMS LANDSCAPE	27
TABLE 3 CELL CULTURE APPLICATIONS	27
LARGE-SCALE MANUFACTURE OF BIOPHARMACEUTICALS AND VACCINES	28
SUSPENSION PROTEINS AND MONOCLONAL ANTIBODIES	28
ADHERENT- CELL-BASED THERAPIES AND VACCINES	28
SMALL-SCALE ADHERENT TO MAKE SOMATIC CELLS, STEM CELLS AND TISSUES	29
FIGURE 1 TECHNOLOGY MATURITY	29
TECHNOLOGY OVERVIEW BY CELL CULTURE TYPE	29
SUSPENSION APPROACHES	29
Stirred Tank	29
TABLE 4 LEADING BIOREACTOR SUPPLIERS, 2014	30
INNOVATION AND CHALLENGES	30
Perfusion	30
Microcarriers	31
Magnetic Applications	31
SINGLE-USE TECHNOLOGY	31
MINI- AND MICRO-BIOREACTORS: CLONE SELECTION AND DEVELOPMENT	32
Commercial Example: TAP/Sartorius Stedim	33
ADHERENT APPROACHES	33
TRADITIONAL ROLLER BOTTLES	33
OTHER SYSTEMS	34
Commercial Example: Icellis by ATMI now part of Pall Corp.	34
NEW UNDERSTANDING OF CELL ATTACHMENT AND DETACHMENT	35
THREE-DIMENSIONAL BIOREACTORS	36
REVENUE ESTIMATE	36
TABLE 5 THREE-DIMENSIONAL BIOREACTOR AND MICROCARRIERS MARKET, THROUGH 2019 (\$ MILLIONS)	36
CHAPTER 5 RESEARCH LANDSCAPE AND CONSUMABLES USED IN THREE-DIMENSIONAL CELL CULTURE	38
MICROPLATES	38
STANDARDS SETTING	38
CONTINUOUS INNOVATION	39
MICROPLATE READERS	39
LIQUID-HANDLING EQUIPMENT	40
CELLOMICS OVERVIEW	40

TOPIC	PAGE NO.
FLUORESCENCE AS DRIVER OF SCREENING	40
HIGH CONTENT SCREENING	41
IMAGING ADVANCES	41
FLOW CYTOMETRY	43
FUTURE VISION FOR HIGH-CONTENT SCREENING	43
<i>TABLE 6 HIGH-CONTENT SCREENING SUPPLIERS AND KEY ATTRIBUTES, JANUARY 2014</i>	43
LABEL-FREE PLATFORMS	43
<i>TABLE 7 LABEL-FREE TECHNOLOGIES AND SUPPLIERS, JANUARY 2014</i>	44
ELECTROPHYSIOLOGY	44
<i>TABLE 8 AUTOMATED PATCH CLAMPING COMPANIES AND TECHNOLOGIES, JANUARY 2014</i>	45
ASSAYS AND ASSAY KITS	45
CELL-BASED ASSAYS: OVERVIEW AND NEWER DEVELOPMENTS	46
CELLS USED IN CELL-BASED ASSAYS	47
Immortalized Cell Lines and Primary Cells	47
Stem Cells at Scale	48
TWO-DIMENSIONAL CULTURES VERSUS THREE- DIMENSIONAL CULTURES	48
REVENUE SUMMARY	49
<i>TABLE 9 LEADING TISSUE PRODUCT SUPPLIERS, JANUARY 2014</i>	49
<i>TABLE 10 LEADING CELL LINE SUPPLIERS, JANUARY 2014</i>	49
<i>TABLE 11 LEADING PRIMARY CELL SUPPLIERS, JANUARY 2014</i>	50
<i>TABLE 12 LEADING STEM CELL SUPPLIERS, JANUARY 2014</i>	51
REVENUE ESTIMATE	51
<i>TABLE 13 CELLS AND REAGENTS USED IN THREE-DIMENSIONAL CELL CULTURE MARKET, THROUGH 2019 (\$ MILLIONS)</i>	51
<i>TABLE 14 CELLS USED IN THREE-DIMENSIONAL CELL CULTURE MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	51
<i>TABLE 15 REAGENTS, MEDIA AND SERA USED IN THREE-DIMENSIONAL CELL CULTURE MARKET, 2013-2019 (\$ MILLIONS)</i>	52
CHAPTER 6 THREE-DIMENSIONAL TECHNOLOGIES AND BASIC PRODUCTS	54
MICROTITER PLATES PROVIDE PLATFORM	54
SUPPORTIVE STANDARDS	54
MICROPLATE WELL INSERTS	55
THREE-DIMENSIONAL CELL CULTURE TECHNOLOGIES	55
THREE-DIMENSIONAL ADOPTION STATUS	55
IMPORTANCE OF TWO-DIMENSIONAL VERSUS THREE- DIMENSIONAL SYSTEMS	55
PARACRINE VERSUS AUTOCRINE SIGNALING	56
BASIC CELL CULTURE VARIABLES	56
CELL ADHESION	56
CELL MIGRATION	57
CELL INVASION	57
BASIC ASSAY TYPES	57
THREE-DIMENSIONAL TECHNOLOGY AND PRODUCTS	57
THREE-DIMENSIONAL MATRICES TO REPLICATE THE EXTRACELLULAR MATRIX	57
FOUNDATIONAL TOOLS: GELS AND BASEMENT MEMBRANES	58
Gels	58

TOPIC	PAGE NO.
Basement Membranes	58
SCAFFOLDS	59
Natural Materials	59
Collagen	59
Laminin	60
Other	60
Artificial Materials	60
Polystyrene Bridges Two-Dimensional to Three-Dimensional	60
INNOVATION EXAMPLES	61
Collagen Innovation	61
Real Architecture for Three-Dimensional Tissues from TAP Biosystems	61
Innovation via Biomimetics	62
3D Biotek	62
Innovation via Finer Pores	62
Alvetex	62
SCAFFOLD-FREE FORMATS	63
Spheroids	63
APPLICATIONS OVERVIEW	64
Liquid-Overlay Technique	64
Centrifugation	64
Hanging-Drop Approach	65
InSphero	66
3D Biomatrix	66
Low-Adhesion Plates	66
Thermo Scientific Nunclon Sphera Surface	67
Ultra-Low-Adhesion Plates	67
Corning Transwell Low-Adhesion	67
Micropatterning	67
CYTOO	68
Hepregen	68
Magnetic Applications	69
Nano3D Biosciences	69
ANALYTICAL METHODS	70
IMAGING	70
LIQUID HANDLING	70
HIGH-THROUGHPUT SCREENING CAPABILITY	70
CONTINUED SPHEROID ADOPTION	71
ORGANOTYPIC MODELS	71
MatTek	71
Life Technologies	72
DIRECTIONAL CULTURE	72
MICROFLUIDICS	73
GLASS/SILICON-BASED PLATFORMS	73
POLYMER-BASED PLATFORMS	74
Typical Configuration	74
Studying Differentiation	74
Scaffolding	74

TOPIC	PAGE NO.
Gel-Free Three-Dimensional Cell Culture	75
Stem Cells	75
Cancer	75
Adoption and Evolution	76
Hurel	76
CHIP TECHNOLOGY	77
Basic Configurations	77
Providing Motion	77
Inflammation	77
Imaging	78
Unmet Need	78
Body on a Chip	78
Wyss Institute	78
Solidus Biosciences	79
BIOPRINTING	80
Overall Three-Dimensional Printing	80
Biomedical Three-Dimensional Printing	80
Technology Derivations	81
Bioink	81
Valve-Based Droplet Ejection	82
Laser Printing	82
Acoustic Ejectors	82
De-Cellularized Extracellular Matrix as Scaffold	82
Viability and Functionality	83
Scaffold-Free Self-Assembly	83
Subassemblies	83
Vasculature	84
Software	84
APPLICATIONS	84
Liver Testing	84
Stem Cells	84
FUTURE CHALLENGES	85
REVENUE SUMMARY	85
<i>TABLE 16 LEADING REAGENT, MEDIA AND MICROPLATE SUPPLIERS, JANUARY 2014</i>	86
REVENUE ESTIMATE	86
<i>TABLE 17 THREE-DIMENSIONAL TECHNOLOGY PRODUCT MARKET, THROUGH 2019 (\$ MILLIONS)</i>	86
<i>TABLE 18 THREE-DIMENSIONAL STANDALONE TECHNOLOGY PRODUCT MARKET, THROUGH 2019 (\$ MILLIONS)</i>	87
CHAPTER 7 ASSAY KITS AND CONTRACT RESEARCH ORGANIZATION SERVICES	89
BASIC CELL CULTURE VARIABLES	89
CELL ADHESION	89
CELL MIGRATION	89
Migration Assays	90
CELL INVASION	90
Cell Invasion Assays	90
VIABILITY AND CYTOTOXICITY	90

TOPIC	PAGE NO.
CELL SIGNALING AND COMMUNICATION	90
ENHANCED FUNCTIONALITY AND CONFIRMING ASSAYS	90
Extracellular Matrix Mimetics Arrays	90
Cell Proliferation Assays	91
Angiogenesis Assay	91
Vascular Permeability Assays	91
Cell Signaling	92
CYTOTOXICITY: A MAJOR CATEGORY	92
Cytotoxic and/or Cytostatic Impacts	92
Screening Strategies	93
PERMEABILITY ASSAYS FOR CELL VIABILITY AND SURVIVAL	93
Lactate Dehydrogenase Enzyme Release Assays	93
Uptake of Dyes Such as Trypan Blue and Alamar Blue Assays	93
Uptake of Neutral Red Uptake for Cell Survival Assays	93
Advantages and Disadvantages	94
METABOLIC ASSAYS FOR CELL VIABILITY AND SURVIVAL	94
MTT Assay	94
Adenosine Triphosphate Assay	94
Disadvantages of Metabolic Assays	94
Fluorometric Approaches	95
Altered Cell Adhesion	95
CELL DEATH ASSAYS	95
Apoptosis versus Necrosis	95
Caspase Activation	95
Membrane Residues	96
Cytochrome C Release from Mitochondria	96
CYSTOSTATIC OR LONG-TERM IMPACT ASSAYS	96
Clonogenic Cell Survival Assay	96
MULTIPLEX ASSAYS	97
COMPOSITE SCREENING STRATEGIES	97
HIGH THROUGHPUT	98
CORRELATION WITH GENE-EXPRESSION DATA	98
THREE-DIMENSIONAL CYTOTOXICITY APPLICATIONS	98
Need for Three-Dimensional Validation	98
Promega	99
3D Biomatrix	99
REVENUE SUMMARY	99
<i>TABLE 19 TYPICAL ASSAY ENDPOINTS AND TESTS</i>	100
LEADING SUPPLIERS	100
<i>TABLE 20 LEADING PRECLINICAL CONTRACT RESEARCH ORGANIZATIONS, JANUARY 2014</i>	101
<i>TABLE 21 ASSAYS KIT AND CONTRACT RESEARCH ORGANIZATIONS SERVICE MARKET, 2013-2019 (\$ MILLIONS)</i>	101
CHAPTER 8 THREE-DIMENSIONAL MODELS FOR CANCER	103
CANCER AT CELLULAR LEVEL OVERVIEW	103
APPROACHES TO DATE	104
CURRENT IN VIVO PRACTICES	104

TOPIC	PAGE NO.
EX VIVO TISSUE SLICES	104
TWO-DIMENSIONAL LEARNINGS AND DRAWBACKS	104
Two-Dimensional Co-Culture Learnings	105
InSphero	105
Genetic Mechanisms	106
THREE-DIMENSIONAL REQUIREMENTS	106
CELL NUMBER AND VIABILITY	106
MIGRATION AND INVASION	106
UNMET NEEDS: ANGIOGENESIS AND IMMUNE SYSTEM EVASION	106
THREE-DIMENSIONAL BENEFITS TO CANCER RESEARCH	106
GREATER DISTINCTION IN CELL MORPHOLOGY AND PROLIFERATION	107
GREATER GENE EXPRESSION AND CELL BEHAVIOR	107
BETTER MODELS OF CELL MIGRATION AND INVASION	107
CELL HETEROGENEITY	108
BREAST CANCER AS A DRIVER OF THREE-DIMENSIONAL CULTURES	108
STRUCTURE, POLARITY AND APOPTOSIS	108
MELANOMA AS A DRIVER OF THREE-DIMENSIONAL CULTURES	108
MOVING TO SPHEROID CONFIGURATIONS	109
Benefits of Spheroids	110
THREE-DIMENSIONAL SYSTEMS IN CANCER RESEARCH	111
MULTICELLULAR TUMOR SPHEROIDS	111
Testing Chemotherapy	111
MULTILAYERED CELL CULTURES	112
Cell-Excreted Extracellular Matrix as a Three-Dimensional Matrix	112
THREE-DIMENSIONAL ENGINEERED SCAFFOLDS	113
NATURAL MATERIALS	113
SYNTHETIC MATERIALS	113
LEARNINGS FROM DRUG SENSITIVITY AND RESISTANCE	114
ALTERED SIGNALING AND SENSITIVITY	114
DRUG RESISTANCE	114
CELLULAR SIGNALING	115
CELLULAR SIGNALING MEDIATED BY INTEGRINS	115
DRUG SCREENING	115
APPROACHES AND ENDPOINTS	115
<i>TABLE 22 COMMON THREE-DIMENSIONAL ASSAYS</i>	116
SPHEROIDS APPLICATIONS	116
<i>TABLE 23 THREE-DIMENSIONAL TUMOR MODELS DEVELOPED FOR DRUG DISCOVERY, JUNE 2014</i>	117
CYTOO	118
METASTASIS VIA THREE-DIMENSIONAL CELL MIGRATION MODEL	118
METASTASIS VIA LUNG-ON-CHIP	119
FUTURE HORIZONS	120
CO-CULTURE	120
VASCULARIZATION	120
CANCER-ASSOCIATED FIBROBLASTS	120
CANCER STEM CELLS	121
COMBINATION THERAPIES	121
BIOLOGICS DEVELOPMENT	121

TOPIC	PAGE NO.
TUMOR RECURRENCE	121
PATIENT-DERIVED CELLS	121
STANDARDS CHALLENGE	121
WE'VE COME A LONG WAY	122
<i>TABLE 24 THREE-DIMENSIONAL CULTURE USED IN CANCER APPLICATIONS MARKET, THROUGH 2019 (\$ MILLIONS)</i>	122
CHAPTER 9 LANDSCAPE FOR TOXICOLOGY AND DRUG SAFETY TESTING	124
TOXICOLOGY BACKGROUND	124
TESTING FOR ADVERSE EFFECTS ON THE SKIN	124
SKIN IRRITATION	125
SKIN CORROSION	125
PHOTOTOXICITY	126
SKIN SENSITIZATION	126
EYE IRRITATION	126
Organotypic Assays	127
Cytotoxicity and Cell Function-Based Assays	127
ACUTE SYSTEMIC TOXICITY	128
ACUTE TOXICITY TESTING	128
CYTOTOXICITY ASSAYS FOR ACUTE TOXICITY TESTING	130
Commercially Available Cytotoxicity Assay Kit	131
CHRONIC AND REPEATED DOSE TOXICITY	131
CHRONIC AND REPEATED DOSE TOXICITY STUDY GOALS	131
Effects of Accumulation and Frequency of Exposure	132
Dosage Levels	132
Duration	133
Reversibility	133
Analysis	133
DEVELOPMENT OF REPEATED DOSE TOXICITY TESTING IN VITRO	133
CARCINOGENICITY AND GENOTOXICITY	133
OVERVIEW	133
IN VITRO METHODS: BACKGROUND AND RECENT DEVELOPMENTS	134
REGULATORY VERSUS DRUG DEVELOPMENT APPLICATIONS	134
Ames Test	135
In Vitro Micronucleus Test	135
EFFORTS TO REDUCE FALSE POSITIVES	135
RECENT INNOVATIONS FOR SCREENING	136
FUTURE CHALLENGE: NON-GENOTOXIC CARCINOGENS	137
REPRODUCTIVE AND DEVELOPMENTAL TOXICITY	137
BACKGROUND	137
FOLLOWING THE REPRODUCTIVE CYCLE	137
Embryotoxicity	138
Male Reproductive Toxicity	138
Female Reproductive Toxicity	139
DEVELOPMENT AND REPRODUCTIVE TOX TESTING TYPES	139
ZEBRAFISH MODEL FOR DEVELOPMENTAL TOXICITY SCREENING	140
COMBINATIONS OF ZEBRAFISH AND STEM CELLS	140
BIOMEDICAL FRONTIERS: MALE TESTIS	141

TOPIC	PAGE NO.
ENDOCRINE DISRUPTOR SCREENING	141
BACKGROUND	141
ENVIRONMENTAL TOXICOLOGY IMPACTS IN VITRO METHODS	141
U.S. Environmental Protection Agency's Endocrine Disruptor Screening Program	142
<i>TABLE 25 IN VITRO AND IN VIVO ASSAYS IN THE TIER 1 SCREENING BATTERY, JANUARY 2014</i>	143
HIGH-PRODUCTION VOLUME CHEMICALS	143
TOXCAST AND TOX 21 INITIATIVES	143
FUTURE CHALLENGE: THYROID DISRUPTION	144
BG1 ASSAY	144
Challenge For Chemical Companies: Depth and Breadth	144
Resource with Full Depth and Breadth	145
TOXICOKINETICS AND ADME	145
IN VITRO DEVELOPMENTS	146
METABOLISM	146
In Vitro Metabolism Offerings	147
Metabolism Reaction Phenotyping for Genetic Polymorphisms	148
Metabolite Profiling	148
Mitochondrial Toxicity	148
ORGANOTYPIC MODELS	149
THREE-DIMENSIONAL MODELS FOR SKIN	149
THREE-DIMENSIONAL CORNEAL SYSTEM	149
ABSORPTION BARRIER MODELS	150
GASTROINTESTINAL	150
LUNG	150
BLOOD-BRAIN BARRIER	150
Real Architecture for Three-Dimensional Tissue Barriers and Extracellular Matrix	151
OTHER APPLICATIONS IN LIVER TOXICITY	152
KIDNEY TOXICITY APPLICATIONS	152
FUTURE CHALLENGE: STEM-CELL DERIVED KIDNEY CELLS	153
PANCREATIC TOXICOLOGY APPLICATIONS	153
CARDIOVASCULAR SAFETY TESTING OF NEW DRUG CANDIDATES	153
COMMERCIAL AVENUE	153
COLLABORATION WITH REGULATORS	154
IN SILICO: MODEL-BASED DRUG DEVELOPMENT	155
MICROELECTRODE ARRAYS BASED ON IMPEDANCE	156
SURROGATE FOR AORTIC RING ASSAY VIA BIOPRINTED MAGNETICS	157
VASODILATOR ACTIVITY	158
THREE-DIMENSIONAL ENGINEERED HEART TISSUES	158
REVENUE ESTIMATE	158
<i>TABLE 26 THREE-DIMENSIONAL CULTURES USED IN PREDICTIVE TOX APPLICATIONS MARKET, THROUGH 2019 (\$ MILLIONS)</i>	158
CHAPTER 10 THREE-DIMENSIONAL CULTURES AND THE LIVER	160
UNIQUENESS AND COMPLEXITY OF LIVER	160
LIVER AS A KEY DRIVER FOR THREE-DIMENSIONAL INNOVATION	160

TOPIC	PAGE NO.
IN VITRO LIVER APPLICATIONS	160
LIVER TOXICITY TESTING	160
PRIMARY HEPATOCYTE USE	161
LEARNINGS FROM MONOLAYER CULTURES	161
LEARNINGS FROM CO-CULTURES CONTRIBUTION TO THE DEVELOPMENT OF CYTOTOXICITY AND THREE-DIMENSIONAL ASSAYS	162
IN VIVO LIVER FUNCTION AND STRUCTURE	162
HEPATOCYTES OR PARENCHYMAL CELLS	162
SPECIALIZED LIVER ENDOTHELIAL CELLS	163
ENDOTHELIAL CELLS SURROUND HEPATOCYTE CORE	163
NON-PARENCHYMAL STELLATE AND KUPFFER CELLS	164
LIVER METABOLISM	164
SUB-CELLULAR LIVER ENZYME FRACTIONS	164
EXTRACELLULAR MATRIX AS A DRIVER OF DIFFERENTIATION`	165
TOXICITY STUDIES AND NON-PARENCHYMAL CELLS' DRIVE IN VITRO DEVELOPMENT	165
CHALLENGES	166
LIVER IN VITRO MODELS	166
ISOLATED PERFUSED RAT LIVER	166
PRECISION-CUT LIVER SLICES	166
HUMAN HEPATOCYTE ISOLATION	167
ISOLATED HEPATOCYTE SHIPPING	167
CO-CULTURES OF HEPATOCYTES AND MACROPHAGES	168
TWO-CHAMBER SYSTEMS	168
MICROPATTERNING	168
THREE-DIMENSIONAL LIVER MODELS	169
TWO-DIMENSIONAL SANDWICH	170
SANDWICH-CULTURE MODEL	170
HYDROGEL THREE-DIMENSIONAL SCAFFOLDS	170
SYNTHETIC SCAFFOLDS	171
Alvetex	171
SELF-ASSEMBLED HEPATOSPHERES	172
HEPATOSPHERES-DERIVED FROM CELL LINES VERSUS PRIMARY CELLS	172
HepG2	172
HepaRG	173
Human and Other Primary Hepatocytes	173
DETECTED HEPATOSPHERE STRUCTURES AND FUNCTIONALITY	173
EXTRACELLULAR MATRIX	173
CELL-CELL CONTACTS: LEARNINGS FROM IN VITRO TOX	174
OXYGEN SUPPLY	174
CO-CULTURE WITH NON-PARENCHYMAL CELLS IN THREE-DIMENSIONAL SPHEROIDS	175
REFINEMENTS TO CO-CULTURE	175
IDEAL CRITERIA	176
DRUG RESISTANCE	176
TRANSPORTER STUDIES	176
ACHIEVING HETEROTYPIC CELL-CELL CONTACTS	176
SUMMARY LEARNINGS	177

TOPIC	PAGE NO.
UNMET NEEDS AND FUTURE DRIVERS OF INNOVATION	177
REGENERATION	177
ACHIEVEMENT OF HEPATOCYTE EXPANSION STILL ELUSIVE	177
INFLAMMATION MODELS	178
Hepregen	178
IMMUNE-MEDIATED DRUG-INDUCED LIVER INJURY	178
Kiyatec	179
HIGH-CONTENT IMAGING AND ANALYSIS	179
STEM CELL-DERIVED HEPATOCYTE POTENTIAL	180
Real Architecture for Three-Dimensional Tissues for Induced Pluripotent Stem Cell Hepatocyte Longevity	180
MORPHOGEN SIGNALING	180
MICROFLUIDICS APPLICATIONS	181
DIELECTROPHORETIC FORCES	181
HepaChip	181
LEARNINGS FROM MICROFLUIDICS	183
SELF-ORGANIZING SYSTEMS	183
CHAPTER 11 THREE-DIMENSIONAL CULTURE ROLE IN STEM CELLS	185
EARLY LEARNINGS	185
EMBRYOGENESIS	185
GROWTH, STRUCTURE AND MORPHOLOGY	186
DIFFERENTIATION	186
DIFFERENTIATION VERSUS PROLIFERATION	186
EXTRACELLULAR MATRIX	186
SOLUBLE FACTORS	187
MECHANICAL FORCES	187
MICRORNAS	188
THREE-DIMENSIONAL STEM CELL CULTURE SYSTEMS	188
PLATE OR CULTURE DISH	188
SPINNER FLASK AND ROTATING WALL VESSEL	188
PERFUSION BIOREACTOR AND MICROCARRIER SYSTEMS	188
SHORTCOMINGS	188
CONTROLLING EMBRYOID BODY FORMATION	189
FORCED AGGREGATION CULTURES	189
HANGING-DROP APPROACH	189
APPLICATIONS	190
STEM CELL MICROENVIRONMENTS	190
STEM CELL MARKERS FOR HIGH-THROUGHPUT SCREENING	191
TERATOMAS AND THE TERATOMA ASSAY	191
REVENUE ESTIMATE	192
<i>TABLE 27 THREE-DIMENSIONAL CULTURES USED IN STEM CELL RESEARCH APPLICATIONS MARKET, THROUGH 2019 (\$ MILLIONS)</i>	192
CHAPTER 12 THREE-DIMENSIONAL NEXT-GENERATION OUTLOOK	194
OVERVIEW	194
CANCER	194
CO-CULTURE	194

TOPIC	PAGE NO.
METASTASES	195
TUMOR RECURRENCE	195
PATIENT-DERIVED CELLS	195
LIVER	195
LIKELY SUBSEGMENTS	195
INTEGRATION WITH -OMICS	196
Transcriptomics	196
Proteomics	197
Metabolomics	198
Metallomics	199
REGENERATIVE MEDICINE AND CELL THERAPY	199
BIOLOGICS DEVELOPMENT	200
CHARACTERIZATION OF NEW CELL LINES	200
FUTURE CHALLENGES	200
CHAPTER 13 COMPANY PROFILES	203
3D BIOMATRIX INC.	203
3D BIOTEK LLC	204
3D CELL TECHNOLOGIES LLC	205
ACEA BIOSCIENCES INC.	205
AKRON BIOTECHNOLOGY LLC	206
AMSBIO LLC	207
APPLIKON BIOTECHNOLOGY	208
BIOGELX LTD.	209
CELLULAR DYNAMICS INTERNATIONAL INC.	209
CORNING LIFE SCIENCES	211
CYTOO INC.	211
GE HEALTHCARE LIFE SCIENCES	212
GREINER BIO-ONE BVBA	213
HEPREGEN CORP.	214
HUREL CORP.	214
INSPHERO AG	216
KIYATEC INC.	216
MEDICYTE GMBH	217
METABOLON INC.	218
MOLECULAR DEVICES LLC	220
NANO3D BIOSCIENCES INC.	221
ORGANOVO HOLDINGS INC.	221
REINNERVATE LTD	222
SEAHORSE BIOSCIENCE	223
STRATATECH CORP.	224
SYNVIVO INC.	225
TAP BIOSYSTEMS	226
THERMO FISHER SCIENTIFIC	227
VISTAGEN THERAPEUTICS INC.	229
WYSS INSTITUTE FOR BIOLOGICALLY INSPIRED ENGINEERING AT HARVARD UNIVERSITY	230
ZEN-BIO INC.	231

TOPIC	PAGE NO.
CHAPTER 14 INTELLECTUAL PROPERTY ANALYSIS	233
<i>TABLE 28 PATENTS AND APPLICATIONS, 2006-2012</i>	233

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE THREE-DIMENSIONAL CELL CULTURE MARKET, THROUGH 2019 (\$ MILLIONS/%)	8
TABLE 1 TISSUE TYPES	11
TABLE 2 CELL TYPES	13
TABLE 3 CELL CULTURE APPLICATIONS	27
TABLE 4 LEADING BIOREACTOR SUPPLIERS, 2014	30
TABLE 5 THREE-DIMENSIONAL BIOREACTOR AND MICROCARRIERS MARKET, THROUGH 2019 (\$ MILLIONS)	36
TABLE 6 HIGH-CONTENT SCREENING SUPPLIERS AND KEY ATTRIBUTES, JANUARY 2014	43
TABLE 7 LABEL-FREE TECHNOLOGIES AND SUPPLIERS, JANUARY 2014	44
TABLE 8 AUTOMATED PATCH CLAMPING COMPANIES AND TECHNOLOGIES, JANUARY 2014	45
TABLE 9 LEADING TISSUE PRODUCT SUPPLIERS, JANUARY 2014	49
TABLE 10 LEADING CELL LINE SUPPLIERS, JANUARY 2014	49
TABLE 11 LEADING PRIMARY CELL SUPPLIERS, JANUARY 2014	50
TABLE 12 LEADING STEM CELL SUPPLIERS, JANUARY 2014	51
TABLE 13 CELLS AND REAGENTS USED IN THREE-DIMENSIONAL CELL CULTURE MARKET, THROUGH 2019 (\$ MILLIONS)	51
TABLE 14 CELLS USED IN THREE-DIMENSIONAL CELL CULTURE MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	51
TABLE 15 REAGENTS, MEDIA AND SERA USED IN THREE-DIMENSIONAL CELL CULTURE MARKET, 2013-2019 (\$ MILLIONS)	52
TABLE 16 LEADING REAGENT, MEDIA AND MICROPLATE SUPPLIERS, JANUARY 2014	86
TABLE 17 THREE-DIMENSIONAL TECHNOLOGY PRODUCT MARKET, THROUGH 2019 (\$ MILLIONS)	86
TABLE 18 THREE-DIMENSIONAL STANDALONE TECHNOLOGY PRODUCT MARKET, THROUGH 2019 (\$ MILLIONS)	87
TABLE 19 TYPICAL ASSAY ENDPOINTS AND TESTS	100
TABLE 20 LEADING PRECLINICAL CONTRACT RESEARCH ORGANIZATIONS, JANUARY 2014	101
TABLE 21 ASSAYS KIT AND CONTRACT RESEARCH ORGANIZATIONS SERVICE MARKET, 2013-2019 (\$ MILLIONS)	101
TABLE 22 COMMON THREE-DIMENSIONAL ASSAYS	116
TABLE 23 THREE-DIMENSIONAL TUMOR MODELS DEVELOPED FOR DRUG DISCOVERY, JUNE 2014	117
TABLE 24 THREE-DIMENSIONAL CULTURE USED IN CANCER APPLICATIONS MARKET, THROUGH 2019 (\$ MILLIONS)	122
TABLE 25 IN VITRO AND IN VIVO ASSAYS IN THE TIER 1 SCREENING BATTERY, JANUARY 2014	143
TABLE 26 THREE-DIMENSIONAL CULTURES USED IN PREDICTIVE TOX APPLICATIONS MARKET, THROUGH 2019 (\$ MILLIONS)	158
TABLE 27 THREE-DIMENSIONAL CULTURES USED IN STEM CELL RESEARCH APPLICATIONS MARKET, THROUGH 2019 (\$ MILLIONS)	192
TABLE 28 PATENTS AND APPLICATIONS, 2006-2012	233

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE THREE-DIMENSIONAL CELL CULTURE MARKET, 2013-2019 (\$ MILLIONS)	9
FIGURE 1 TECHNOLOGY MATURITY	29